|
|
|
|
|
Sponsors and Collaborators: |
New York University School of Medicine National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00025311 |
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of intrathecal or intraventricular topotecan in treating recurrent, progressive, or refractory cancer that is metastatic to the lining around the brain.
Condition | Intervention | Phase |
Metastatic Cancer |
Drug: topotecan hydrochloride |
Phase I |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Topotecan hydrochloride Topotecan |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase I Study Of Seven Day Continuous Intrathecal/Intraventricular Infusion Of Topotecan For Patients With Recurrent, Progressive Or Refractory Leptomingeal Disease |
Study Start Date: | May 2001 |
OBJECTIVES:
OUTLINE: This is a dose-escalation study. Patients are stratified according to disease (leukemia or lymphoma vs solid tumor or other malignancy).
Patients receive topotecan intrathecally or intraventricularly continuously on days 1-7. Treatment repeats every 21 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose- limiting toxicity.
Patients are followed for 6 months.
PROJECTED ACCRUAL: A maximum of 50 patients (25 per stratum) will be accrued for this study.
Ages Eligible for Study: | up to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Neoplastic meningitis/leptomeningeal metastasis refractory to conventional therapy and other therapies of higher priority, defined as:
Stratum A:
Stratum B:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Stratum B:
Hepatic:
Renal:
Neurologic:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Other concurrent systemic cancer chemotherapy for leukemia or lymphoma allowed with the following restrictions:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, New York | |||||
Herbert Irving Comprehensive Cancer Center | |||||
New York, New York, United States, 10032 | |||||
NYU School of Medicine's Kaplan Comprehensive Cancer Center | |||||
New York, New York, United States, 10016 | |||||
France | |||||
CHU Pitie-Salpetriere | |||||
Paris, France, 75651 |
New York University School of Medicine |
National Cancer Institute (NCI) |
Study Chair: | Jonathan L. Finlay, MB, ChB | New York University School of Medicine |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000068949, NYU-0005H, NYU-0041H, NCI-G01-2018 |
First Received: | October 11, 2001 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00025311 |
Health Authority: | United States: Federal Government |
|
|
|
|